Chemistry:Samatasvir
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C47H48N8O6S2 |
| Molar mass | 885.07 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.[1]
Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex.[2] While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.[3]
See also
- Discovery and development of NS5A inhibitors
References
- ↑ "A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4". Journal of Hepatology 60 (5): 920–7. May 2014. doi:10.1016/j.jhep.2014.01.003. PMID 24434503.
- ↑ "In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus". Antimicrobial Agents and Chemotherapy 58 (8): 4431–42. August 2014. doi:10.1128/AAC.02777-13. PMID 24867983.
- ↑ Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov
 |  |
